Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial

Background: In addition to supportive therapy, antiviral therapy is an effective treatment for coronavirus disease 2019 (COVID-19). Objective: To compare the efficacy and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19 patients. Methods: We conducted a prospective, randomized, contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chang, Zhang, Yi, Huang, Jianying, Yin, Ping, Cheng, Zhenshun, Wu, Jianyuan, Chen, Song, Zhang, Yongxi, Chen, Bo, Lu, Mengxin, Luo, Yongwen, Ju, Lingao, Zhang, Jingyi, Wang, Xinghuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443786/
https://www.ncbi.nlm.nih.gov/pubmed/34539392
http://dx.doi.org/10.3389/fphar.2021.683296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443786/
https://www.ncbi.nlm.nih.gov/pubmed/34539392
http://dx.doi.org/10.3389/fphar.2021.683296

Ejemplares similares